DataString Consulting Company Logo
DataString Consulting Company Logo
Quizartinib Tablets Market
Home»Top Market Reports»Quizartinib Tablets Market

Quizartinib Tablets Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802161, Published - April 2025

Segmented in Dosage Form (Immediate Release, Delayed Release), Therapeutic Use (Acute Myeloid Leukemia, Aggressive Systemic Mastocytosis, Other Oncological Conditions), End-User, Purchase Mode and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Quizartinib Tablets Market Outlook

The market, for Quizartinib tablets was estimated at $612.1 million in 2024; and it is anticipated to increase to $1.0 billion by 2030 with projections indicating a growth to around $1.6 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 9.3% over the forecast period. The notable increase in market activity underscores the enduring importance of Quizartinib Tablets within the healthcare sector. Factors such as the growing occurrence of acute myeloid leukemia. An ailment for which Quizartinib is frequently prescribed. And substantial investments in pharmaceutical industries worldwide have further solidified the products significance. Additionally progress in studies and continual research endeavors to enhance the effectiveness of Quizartinib Tablets are also playing a role, in driving the products market traction forward.


Quizartinib Tablets are also referred to as AC220 tablets. Are taken orally to inhibit FLT inhibitors for the treatment of patients with acute myeloid leukemia who have an FLT2 ID mutation specifically. The effectiveness and lower likelihood of relapse when using this medication have contributed to its increasing popularity in times. Moreover improvements in accuracy increased knowledge about the illness and the option of using Quizartinib Tablets in conjunction with other therapies have all led to a surge, in worldwide demand.


Market Size Forecast & Key Insights

2019
$612M2024
2029
$1.5B2034

Absolute Growth Opportunity = $877M

The Quizartinib Tablets market is projected to grow from $612.1 million in 2024 to $1.49 billion in 2034. This represents a CAGR of 9.3%, reflecting rising demand across Acute Myeloid Leukemia Treatment, Relapsed or Refractory AML Treatment and Clinical Trials for Other Malignancies.

The Quizartinib Tablets market is set to add $877 million between 2024 and 2034, with manufacturer targeting Aggressive Systemic Mastocytosis & Other Oncological Conditions Therapeutic Use projected to gain a larger market share.

With Growing prevalence of acute myeloid leukemia, and Technological advancements in drug discovery, Quizartinib Tablets market to expand 143% between 2024 and 2034.

Opportunities in the Quizartinib Tablets Market

Responding to Evolving Consumer Needs in Emerging Markets

The increasing prevalence of AML in developing countries results in a need for efficient treatment options. The utilization of Quizartinib tablets that demonstrate effectiveness, in challenging AML instances could address this demand by adapting product availability and pricing to match the changing market dynamics in these areas.

Technological Innovations Drive Demand and Market Expansion through Strategic Collaborations

The fast progress in the field of chemistry requires ongoing improvements in cancer treatment methods to keep up with the advancements in technology. Quizartinib Tablets are inhibitors of FLT3 ITD and AML that could greatly benefit from this technological advancement. These tablets provide a treatment approach in cases where traditional therapies may not only be effective enough. By integrating drug discovery methods with targeted Quizartinib therapy, new avenues, for revenue generation could be explored while addressing the unmet needs of patients.

Collaborating with companies and research institutions may accelerate the progress of developing and bringing Quizartinib tablets to market swiftly. This approach to growth could promote the exchange of knowledge and resources. Enable the joint development of enhanced treatment protocols for AML patients—helping to advance the position, in the market quickly.

Growth Opportunities in North America and Asia Pacific

Asia Pacific Outlook

In the Asia Pacific region market for Quizartinib Tablets is projected to show growth in the near future due to an increase in AML patients caused by an aging population and changes in lifestyle which are driving factors for market expansion in this sector. Countries such as China, Japan and India have a stake in the market thanks to the improvement of healthcare facilities and government efforts towards healthcare progress. The competition scenario features a mix of international companies competing for a leading position, in the market. The increasing recognition among the public about AML and the advantages of Quizartinib tablets is expected to boost market expansion, in the Asia Pacific region.

North America Outlook

The market for Quizartinib Tablets in North America is on a rise due to the growing number of cases of acute myeloid leukemia and significant investments in research and development driving this trend forward. High healthcare standards and a established regulatory framework contribute to the increasing use of these targeted therapy tablets which in turn pushes manufacturers to meet the rising demand. Competition is tough in this region with players such as Daiichi Sankyo and AstraZeneca strengthening their market approaches, for a larger share of the market. The Quizartinib Tablets market in North America is anticipated to experience growth due, to the rise of technology trends and personalized medicine approaches.

North America Outlook

The market for Quizartinib Tablets in North America is on a rise due to the growing number of cases of acute myeloid leukemia and significant investments in research and development driving this trend forward. High healthcare standards and a established regulatory framework contribute to the increasing use of these targeted therapy tablets which in turn pushes manufacturers to meet the rising demand. Competition is tough in this region with players such as Daiichi Sankyo and AstraZeneca strengthening their market approaches, for a larger share of the market. The Quizartinib Tablets market in North America is anticipated to experience growth due, to the rise of technology trends and personalized medicine approaches.

Asia Pacific Outlook

In the Asia Pacific region market for Quizartinib Tablets is projected to show growth in the near future due to an increase in AML patients caused by an aging population and changes in lifestyle which are driving factors for market expansion in this sector. Countries such as China, Japan and India have a stake in the market thanks to the improvement of healthcare facilities and government efforts towards healthcare progress. The competition scenario features a mix of international companies competing for a leading position, in the market. The increasing recognition among the public about AML and the advantages of Quizartinib tablets is expected to boost market expansion, in the Asia Pacific region.

Growth Opportunities in North America and Asia Pacific

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, United Kingdom, Japan, China are expected to grow at 6.8% to 9.8% CAGR

2

Emerging Markets : Brazil, India, Singapore are expected to grow at 8.9% to 11.6% CAGR

Market Analysis Chart

Analyzing the market trends related to Quizartinib Tablets reveals that different factors play a role in determining their supply and demand levels. One of the reasons driving the use of Quizartinib Tablets is their established success in treating acute myeloid leukemia a specific form of cancer impacting the blood and bone marrow. With the escalating global incidence of medical ailments comes a heightened requirement, for dependable and efficient therapies. An area where Quizartinib Tablets have been making significant contributions.

Recent Developments and Technological Advancement

December 2024

Zenolabs shared news about the completion of phase III clinical trials, for their Quizartinib tablets. The results showed promise in treating acute myeloid leukemia .

October 2024

MedSource shared that there has been an increase in the worldwide supply of Quizartinib tablets due, to the growing occurrence of AML.

August 2024

Regentix started an investigation to assess how the use of Quizartinib tablets in combination, with other common AML medications could enhance the rate of patient response.

Quizartinib Tablets have emerged as a breakthrough in the healthcare sector with a specific focus on oncology—a noteworthy trend to discuss when talking about recent advancements in this field of medicine. These tablets have displayed effectiveness, in individuals facing acute myeloid leukemia conditions and have significantly impacted both the patients lives and the pharmaceutical market as a whole. The Quizartinib Tablets market is currently experiencing a period of change and growth.

Impact of Industry Transitions on the Quizartinib Tablets Market

As a core segment of the Pharmaceutical industry, the Quizartinib Tablets market develops in line with broader industry shifts. Over recent years, transitions such as Evolving Treatment Protocols and Streamlined Drug Manufacturing have redefined priorities across the Pharmaceutical sector, influencing how the Quizartinib Tablets market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Evolving Treatment Protocols:

The pharmaceutical field has experienced a change with the arrival of Quizartinib Tablets designed mainly for the precise treatment of acute myeloid leukemia . The integration of these tablets into treatment plans has expanded the scope of therapy options to patients dealing with this condition effectively. Quizartinibs distinct method of operation involves targeting the FLT3 gene mutation commonly found in AML cases which enables a targeted strategy, in fighting the disease and subsequently enhancing patient survival rates and diagnostic outcomes.

2

Streamlined Drug Manufacturing:

The FDAs recognition of Quizartinib Tablets as an Orphan Drug has led to changes in the manufacturing sector by promoting specialization and efficiency in production methods. This designation highlights the drugs effectiveness in treating illnesses and motivates manufacturers to prioritize the production of these sought after specialized medications. As a result of this shift in focus by manufacturers there has been a surge in the availability of Quizartinib Tablets making treatment more accessible, for patients who were previously overlooked.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Quizartinib Tablets market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Growing Prevalence of Acute Myeloid Leukemia, and Increase in Healthcare Expenditure

The rising number of Acute Myeloid Leukemia cases globally is also a driver behind the market expansion of Quizartinib Tablets. Given that AMLs the predominant form of acute leukemia among adults there is also a growing need for impactful medications such as Quizartinib Tablets to address this pressing issue effectively. The drugs capacity to impede the proliferation of cells positions itself as a crucial element, in combating this persistent illness.
Increased healthcare costs worldwide are also also a factor for the Quizartinib Tablets markets growth potential as countries allocate more resources to healthcare services and make advanced treatment options such as Quizartinib Tablets more accessible, to a wider population.
In times the progress in drug discovery tools has also resulted in the emergence of more effective and safer choices such as Quizartinib Tablets being introduced to the market scene. Thanks to technologies enabling thorough molecular and genetic investigations the development of targeted medications that exhibit precise actions is also made feasible.

Restraint: Regulatory Challenges

The strict rules and regulations that oversee the approval of medications in nations can pose considerable obstacles for Quizartinib Tablets in its journey to market availability and success. These regulations mandate testing and trials for drugs prior, to their release leading to a costly and time intensive procedure. As a result of these factors the achievement of market entry and profitability could be postponed, thereby restricting market expansion.

Challenge: High Treatment Costs

The significant costs associated with the use of Quizartinib Tablets present a challenge in the healthcare sector for cancer treatment needs like acute myeloid leukemia patients due to the intensive research and development involved in their production process that demands higher pricing to offset expenses incurred therein Consequently this elevated treatment expense hinders accessibilities among patients, from varying socioeconomic backgrounds limiting the markets growth prospects extensively.

Supply Chain Landscape

Raw Material Procurement

Department of Pharmaceuticals

Active Pharmaceutical Ingredients

Drug Synthesis

Daiichi Sankyo

Deciphera Pharmaceuticals

Tablet Formulation
Baxter BioPharma Solutions / Recipharm
Distribution & Retail
Walgreens / CVS Health
Raw Material Procurement

Department of Pharmaceuticals

Active Pharmaceutical Ingredients

Drug Synthesis

Daiichi Sankyo

Deciphera Pharmaceuticals

Tablet Formulation

Baxter BioPharma Solutions

Recipharm

Distribution & Retail

Walgreens

CVS Health

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Cancer Treatment
Pharmaceutical
Daiichi Sankyo
Developing targeted therapeutics for optimal patient care
Leukemia Management
Healthcare
Ambit Biosciences
Advancing therapies for hematologic malignancies to improve patient outcomes
Research & Development
Bio-Sciences
R&D Systems
Investing in scientific research to discover the potential of Quizartinib Tablets

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Quizartinib Tablets market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Quizartinib Tablets in Relapsed or Refractory AML Treatment, Acute Myeloid Leukemia Treatment and Clinical Trials for Other Malignancies

Relapsed or Refractory AML Treatment

Quizartinib tablets are commonly used for treating refractory acute myeloid leukemia cases with FTL 2 mutations because they are effective in targeting the FLT 2 gene and have been proven to enhance survival rates in patients with refractory AML condition. Major pharmaceutical companies such as Novartis and Pfizer have incorporated Quizartinib into their treatment plans, for AML patients well.

Acute Myeloid Leukemia Treatment

Quizartinib tablets are essential in treating acute myeloid leukemia . Belonginging in the category of protein kinase inhibitors Quizartinib specifically targets FLT gene mutations that play a role in AML development. By blocking the growth of cancer cells these tablets provide doctors with a weapon against this disease. Pharmaceutical companies such as Daiichi Sankyo have established a presence, in the AML treatment market with Quizartinib.

Clinical Trials for Other Malignancies

Quizartinib tablets are not only just limited to treating acute myeloid leukemia. Are also undergoing clinical trials for treating different forms of cancers as well in various research settings and pharmaceutical companies due to the wide ranging effectiveness of protein kinase inhibitors in combination treatments for battling differents of cancers thereby showcasing the potential of Quizartinib tablets beyond its initial use and the scope, for market growth opportunities.

Quizartinib Tablets vs. Substitutes:
Performance and Positioning Analysis

Quizartinib Tablets, superior in mitigating acute myeloid leukemia, outperform alternatives due to their unique efficient targeted formula. With unparalleled market positioning, they exhibit prominent growth potential, revolutionizing leukemia treatments. These Alternatives specially Ponatinib Hydrochloride has experienced a rapid growth as detailed in our latest report.

Quizartinib Tablets
  • Midostaurin Capsules /
  • Ponatinib Hydrochloride /
  • Gilteritinib Tablets
    Effective in treating acute myeloid leukemia patients with FMS-like tyrosine kinase 3 (FLT3) genetic mutation, Potentially improved survival rates
    Potential side effects
    More affordable, wider accessibility
    Lower efficacy rate, increased side-effects

Quizartinib Tablets vs. Substitutes:
Performance and Positioning Analysis

Quizartinib Tablets

  • Effective in treating acute myeloid leukemia patients with FMS-like tyrosine kinase 3 (FLT3) genetic mutation, Potentially improved survival rates
  • Potential side effects

Midostaurin Capsules / Ponatinib Hydrochloride / Gilteritinib Tablets

  • More affordable, wider accessibility
  • Lower efficacy rate, increased side-effects

Quizartinib Tablets, superior in mitigating acute myeloid leukemia, outperform alternatives due to their unique efficient targeted formula. With unparalleled market positioning, they exhibit prominent growth potential, revolutionizing leukemia treatments. These Alternatives specially Ponatinib Hydrochloride has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Quizartinib Tablets market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Quizartinib Tablets across Hospitals, Chemotherapy Centers, and Research Institutes Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Novartis International AG, Acerta Pharma, and Apellis Pharmaceuticals Inc by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, Drug Synthesis, and Tablet Formulation. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Quizartinib Tablets segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (Department of Pharmaceuticals, Active Pharmaceutical Ingredients), Drug Synthesis (Daiichi Sankyo, Deciphera Pharmaceuticals), and Tablet Formulation. Our parallel substitute analysis examines Midostaurin Capsules, Ponatinib Hydrochloride, and Gilteritinib Tablets, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Novartis International AG, Acerta Pharma, and Apellis Pharmaceuticals Inc, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Quizartinib Tablets market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Quizartinib Tablets Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 669 million
Revenue Forecast in 2034USD 1.49 billion
Growth RateCAGR of 9.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024612 million
Growth OpportunityUSD 877 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024612 million USD
Market Size 2027799 million USD
Market Size 2029954 million USD
Market Size 20301.04 billion USD
Market Size 20341.49 billion USD
Market Size 20351.63 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDosage Form, Therapeutic Use, End-User, Purchase Mode
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledNovartis International AG, Acerta Pharma, Apellis Pharmaceuticals Inc, ARIAD Pharmaceuticals Inc, Asana BioSciences LLC, Astellas Pharma Inc, AstraZeneca Plc, Athenex Inc, Blueprint Medicines Corp, Celgene Corp, Cell Therapies Pty Ltd and Daiichi Sankyo Co Ltd.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Quizartinib Tablets Market Size, Opportunities & Strategic Insights, by Dosage Form

4.1Immediate Release
4.2Delayed Release
Chapter 5

Quizartinib Tablets Market Size, Opportunities & Strategic Insights, by Therapeutic Use

5.1Acute Myeloid Leukemia
5.2Aggressive Systemic Mastocytosis
5.3Other Oncological Conditions
Chapter 6

Quizartinib Tablets Market Size, Opportunities & Strategic Insights, by End-User

6.1Hospitals
6.2Chemotherapy Centers
6.3Research Institutes
Chapter 7

Quizartinib Tablets Market Size, Opportunities & Strategic Insights, by Purchase Mode

7.1Prescription-based
7.2Over-the-counter
Chapter 8

Quizartinib Tablets Market, by Region

8.1North America Quizartinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Quizartinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Quizartinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Quizartinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Quizartinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Quizartinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Novartis International AG
9.2.2Acerta Pharma
9.2.3Apellis Pharmaceuticals Inc
9.2.4ARIAD Pharmaceuticals Inc
9.2.5Asana BioSciences LLC
9.2.6Astellas Pharma Inc
9.2.7AstraZeneca Plc
9.2.8Athenex Inc
9.2.9Blueprint Medicines Corp
9.2.10Celgene Corp
9.2.11Cell Therapies Pty Ltd
9.2.12Daiichi Sankyo Co Ltd.